QBiotics to present advances from its oncology and wound healing programmes at key conferences in October and November

Brisbane, 12 October 2023

QBiotics Group Limited (QBiotics) is pleased to announce details of the key scientific, clinical and corporate conferences where it will be presenting in October and November.

Corporate presentations

  • Bell Potter Healthcare Conference, 14, 15 and 16 November (Virtual Conference)
    QBiotics Chief Executive Officer & Managing Director, Dr Victoria Gordon will give a presentation on the Company, including updates on the oncology and wound healing programmes 3.30pm to 3:55pm on 16 November 2023.
  • BIO Europe, 6-8 November in Munich, Germany.
    Richard Godfrey representing QBiotics in Business Development will give a presentation on the Company and tigilanol tiglate, its lead oncology programme at 2:00pm to 2:15pm on Tuesday, 7 November in the San Sabastian Room.

Scientific conferences

  • Veterinary Cancer Society Annual Conference, 12-14 October in Reno, Nevada, US.
    QBiotics Chief Veterinary Officer, Dr Pamela Jones will present a poster titled “Diagnostic viability of canine mast cell tumour tissue biopsy samples acquired 5-10 minutes post tigilanol tiglate treatment” on 13 October 2023.
  • 31st International Symposium on Chemistry of Natural Products and the 11th International Congress on BioDiversity, 15-19 October in Napoli, Italy.
    QBiotics Chief Scientific Officer & Executive Director, Dr Paul Reddell will present a Plenary session titled “From rainforest to clinic: A case study of the scientific and developmental challenges in commercializing natural products as pharmaceuticals” on 15 October 2023.
    The QBiotics team will also present three posters describing preclinical data on its lead oncology drug, tigilanol tiglate and its wound healing drug candidate, EBC-1013.
  • 7th Annual Dermatology Drug Development Summit, 31 October-2 November in Boston, Massachusetts.
    Dr Jason Cullen from QIMR Berghofer Medical Research Institute will give an oral presentation as well as a poster presentation on the therapeutic applications of tigilanol tiglate and EBC-1013 epoxytiglianes as novel treatments for skin lesions and wound healing.
  • Connective Tissue Oncology Society Annual Meeting, 1-4 November in Dublin, Ireland.
    Dr Edmund Bartlett, MD of Memorial Sloan Kettering Cancer Center, New York will present a poster outlining QBiotics’ ongoing Phase II clinical study on its lead molecule, tigilanol tiglate entitled “A pilot Phase II study to evaluate the small molecule tigilanol tiglate in patients with advanced soft tissue sarcoma: clinical trial in progress” on 2 November 2023 from 5.30pm to 6.30pm. Abstract ID: 1566620.
  • Society for Immunotherapy of Cancer Annual Meeting, 1-5 November in San Diego, California.
    Dr Jason Cullen of QIMR Berghofer Medical Research Institute will present a poster on the mode of action of QBiotics lead oncology drug entitled, “Tigilanol tiglate is a small molecule oncolytic that induces immunogenic cell death and promotes immune cell infiltration into human tumors” on Friday 3rd November from 12:12-1:30 pm and 5:10 – 6:40pm. Abstract No. 1091.

To arrange a meeting at, or around the conferences noted above where QBiotics or our collaborators are presenting, please contact tracey.mynott@qbiotics.com

Please note that event participation and specific dates are subject to change.


communications@qbiotics.com or


jane.lowe@irdepartment.com.au  +61 411 117 774



QBiotics is an unlisted public Australian life sciences company that discovers and develops pharmaceuticals derived from nature to address unmet medical needs in humans and companion animals. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.

QBiotics’ business model is to develop products that have applications in both veterinary and human markets. Success in the veterinary programme validates QBiotics technology and informs the early stages of human development, while having the potential to generate early revenue.

QBiotics’ lead oncology drug, tigilanol tiglate, is a small molecule targeting a range of solid tumours and is currently in human clinical Phase II development. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.

QBiotics’ lead wound healing drug candidate is a small molecule targeting a range of wounds including chronic and acute wounds and burns. Preparation is in progress for a first-in-human Phase I/IIa clinical trial in patients with venous leg ulcers.